Harrow announces issuance of J-Code for Iopidine 1%

Harrow (HROW) announced that Iopidine 1% has been assigned a permanent J-Code by the Centers for Medicare & Medicaid Services, CMS. Effective July 1, 2026, Iopidine 1% will be reimbursed when administered in the in-office setting. J-Codes are CMS billing designations that allow physicians to be reimbursed directly for drugs administered in their offices. The assignment of a permanent J-Code removes a longstanding practical barrier to routine use of Iopidine 1% for office-based procedures, making it administratively and economically feasible for physicians to incorporate Iopidine 1% into standard glaucoma and ophthalmic laser procedure workflows.